MDxHealth SA (MDXH)
About MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $29.1M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $29.1M
- Shares outstanding
- 70.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 14, 2008
MDxHealth SA (MDXH) Stock Price
- Trading 92% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MDxHealth SA.
Write a review
News about MDxHealth SA
News & sentiment via Polygon.io
MDxHealth SA: frequently asked questions
Is MDxHealth SA an American company?
MDxHealth SA is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is MDxHealth SA publicly traded?
Yes — MDxHealth SA is a publicly traded company. Its stock trades under the ticker symbol MDXH on the NASDAQ.
What does MDxHealth SA do?
MDxHealth SA is an American Medical Devices company in the Health & Beauty sector.
